Decision to Limit or Withdraw Specific Therapies for Advanced Cancer and Hematological Malignancies. (WHATELSE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02841124|
Recruitment Status : Completed
First Posted : July 22, 2016
Last Update Posted : July 27, 2016
|Condition or disease||Intervention/treatment||Phase|
|Advanced Cancer Ethics||Other: interviews||Not Applicable|
This study explores the decision-making process for patients with advanced cancer when the question to imit or withdraw specific therapies (DLWT) is raised, with a cross-analysis of physicians and pts points of view.
This study took place in 5 oncology and hematology units : 2 university hospitals, 1 general hospital, 1 cancer center and 1 private hospital. The study included two different approaches: an epidemiological section to identify the prevalence of these situations in different institutions and a qualitative study section exploring factors influencing the decision process. The epidemiological analysis included all hospitalized patients identified with advanced cancer for whom the question of DLWT was raised in a given week or during the two weeks preceding the investigation.
The qualitative analysis was based on interviews with the referent oncologist (or hematologist) and his patient (conducted by a physician and a psychologist respectively) as well as interviews with other partners involved in the situation (care staff and relatives) depending on the center. Researchers also participated in multidisciplinary meetings and monitored changes in the decision over a three month period.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||21 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Decision to Limit or Withdraw Specific Therapies for Advanced Cancer and Hematological Malignancies : Physicians and Patients Points of View and Interactions.|
|Study Start Date :||January 2011|
|Actual Primary Completion Date :||August 2011|
|Actual Study Completion Date :||August 2011|
face-to-face interviews with the referent oncologist (or hematologist) and his patient (conducted by a physician and a psychologist respectively) as well as interviews with other partners involved in the situation (care staff and relatives)
- interviews with physicians, patients and relatives [ Time Frame: 6 months ]A thematic analysis induces the creation of a set of themes and concepts clustered by relevance into a tree structure. The thematic tree structure constitutes the dataset of interest.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02841124
|Centre Hospitalier Universitaire de Besançon|
|Besancon, France, 25000|
|Centre Hospitalier de Colmar|
|Colmar, France, 68000|
|Dijon, France, 21000|
|Centre Hospitalier Universitaire St Antoine|
|Paris, France, 75012|
|Centre de Luttre Contre le Cancer Alexis Vautrin|
|Vandœuvre-lès-Nancy, France, 54519|